BUDGET IMPACT ANALYSIS OF THE PERMANENT ENDOVASCULAR ADHESIVE CLOSURE SYSTEM IN THE TREATMENT OF VENOUS REFLUX AND CHRONIC VENOUS INSUFFICIENCY (CVI) IN TURKEY
Author(s)
Ozdemir Saltik Z, Akgul T, Can H, Copur F, Askin E
Medtronic, Istanbul, Turkey
Presentation Documents
OBJECTIVES: To estimate the 3-year budget impact of Venaseal venous closure system for the treatment of venous reflux disease and CVI by the permanent, complete, endovascular adhesive closure of the great saphenous vein and associated varicosities in the Turkish setting. METHODS: Payer perspective is applied. Only direct costs are considered. Literature research is performed for global and local epidemiologic data. Comparators are identified as the other peripheral venous adhesive embolization products for the same indications in the positive list. Device and procedure costs are derived from positive list prices. For Venaseal, proposed reimbursement price is taken. Complication, re-hospitalization rates and length-of-stay are similar, thus related costs are ignored. Unilateral-bilateral intervention rates are based on reported rates from clinical studies, supported and confirmed by expert opinions. Current market share estimates are based on public tender results database. Further market share estimations are based on Medtronic sales data and forecast. RESULTS: compared with the other peripheral venous embolization products in the market, Venaseal is a qualified and latest technology treatment option for CVI, predicted to provide 0.89 million TL, 1.6 million TL, and 2.4 million TL savings in first, second and third years respectively. Total estimated cost-saving swill be approximately 4.8 million TL. CONCLUSIONS: Endovascular adhesive closure technique for varicose veins is an innovative, non-thermal, non-tumescent therapy option for CVI, compared to radiofrequency ablation, stripping and surgery. It offers an effective outpatient alternative to endovascular therapies in patients with below-the-knee and bilateral venous disorders and those unable to tolerate post-procedure compression, where patients can get back to their daily routines immediately without being hospitalized. Besides the cost-savings it offers in comparison with the other on-the-market adhesive closure systems, with its ease-of-use, reliable and reproducible results, Venaseal represents the next generation in endovascular technology and should be the non-tumescent treatment alternative for CVI.
Conference/Value in Health Info
2016-10, ISPOR Europe 2016, Vienna, Austria
Value in Health, Vol. 19, No. 7 (November 2016)
Code
PMD26
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Cardiovascular Disorders